Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)

Summary

This expanded access program provides investigational levacetylleucine to patients with Ataxia-Telangiectasia who are not eligible for clinical trials and have no satisfactory alternative therapies.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications